This is a preview of subscription content, log in via an institution to check access.
Reference
Decision Resources. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen. Media Release : 14 May 2013. Available from: URL: http://www.decisionresourcesgroup.com
Rights and permissions
About this article
Cite this article
Multiple myeloma: improved survival needed to justify costs. PharmacoEcon Outcomes News 679, 11 (2013). https://doi.org/10.1007/s40274-013-0454-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0454-y